Leukemia · 2019 · 24 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyHematologic OncologyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesHematologic Malignancy TherapyAnti-cd20 Antibody TherapyCell Cycle Arrest SignalingLutetium-177 ChemistryLymphoma ChemotherapyNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma TreatmentProliferation AssaysRituximab-based Therapy
Abstract Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 ( 177 Lu)-lilotomab (Betalutin ® ) was investigated in preclinical models of NHL. In SCID mice bearing DOHH2 (transformed follicular lymphoma, FL) cell xenografts, 177 Lu-lilotomab significantly delayed tumor growth, even at low activity (100 MBq/kg). In athymic mice bearing OCI-Ly8 (diffuse large B-cell lymphoma, DLBCL) or Ramos (Burkitt’s lymphoma) cell xenografts, 177 Lu-lilotomab activity had to be increased to 500 MBq/kg to show a significant tumor growth delay. Clonogenic and proliferation assays showed that DOHH2 cells were highly sensitive to 177 Lu-lilotomab, while Ramos cells were the least sensitive, and U2932 (DLBCL), OCI-Ly8, and Rec-1 (mantle cell lymphoma) cells displayed intermediate sensitivity. The strong 177 Lu-lilotomab cytotoxicity observed in DOHH2 cells correlated with reduced G2/M cell cycle arrest, lower WEE-1- and MYT-1-mediated phosphorylation of cyclin-dependent kinase-1 (CDK1), and higher apoptosis. In agreement, 177 Lu-lilotomab efficacy in vitro, in vivo, and in patient samples was increased when combined with G2/M cell cycle arrest inhibitors (MK-1775 and PD-166285). These results indicate that 177 Lu-lilotomab is particularly efficient in treating tumors with reduced inhibitory CDK1 phosphorylation, such as transformed FL.
34
THE TOXICITY OF POISONS APPLIED JOINTLY1
C. I. Bliss · Annals of Applied Biology · 1939 · 2.4K citations
Pharmacy, Pharmacology, Toxicology +15
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text
Life Sciences, Immunology, Pathology +14
Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations
Medicine, Immunology, Oncology +14
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamarı́a, Cédric Barrière, Antonio Cerqueira et al. · Nature · 2007 · 1.1K citations
Carla Casulo, Michelle Byrtek, Keith Dawson et al. · Journal of Clinical Oncology · 2015 · 844 citations · Full text
Medicine, Immunology, Oncology +11